Age | |
Mean ± SD | 60.0 ± 11.6 |
Median (IQR) | 62.0 (54.0–69.0) |
Sex | |
Men, n (%) | 4 (5) |
Women, n (%) | 78 (95) |
Disease duration (in years) | |
Mean ± SD | 7.7 ± 7.1 |
Median (IQR) | 6.0 (2.0–11.3) |
Leroy subset, n (%) | |
LSSc | 0 (0) |
LcSSc | 61 (74) |
DcSSc | 21 (26) |
NVC pattern, n (%) | |
Early | 29 (36) |
Active | 24 (29) |
Late | 24 (29) |
Normal — Aspecific changes | 5 (6) |
Antibodies profile*, n (%) | |
ACA | 39 (48) |
Anti-topo | 22 (27) |
Anti-RNA pol III | 3 (4) |
Pm-Scl | 1 (1) |
Peripheral vascular therapy, n (%) “yes” | |
Prostacyclins | 38 (46) |
Calcium antagonists | 71 (87) |
Endothelin receptor antagonists | 1 (1) |
Phosphodiesterase type 5 inhibitor | 0 (0) |
Pulmonary-vascular therapy | 5 (6) |
Prostacyclins | 0 (0) |
Endothelin receptor antagonists | 4 (5) |
Phosphodiesterase type 5 inhibitor | 1 (1) |
Lost to followup, n | 2 |
Due to logistic reasons | 0 |
Non-SSc-related reasons | 0 |
SSc-related reasons | 2 |
↵* Missing for 1 patient for logistical reasons. NVC: nailfold videocapillaroscopy; IQR: interquartile range; LSSc: limited systemic sclerosis; LcSSc: limited cutaneous systemic sclerosis; DcSSc: diffuse cutaneous systemic sclerosis; ACA: anticentromere antibodies; anti-topo: antitopoisomerase; SSc: systemic sclerosis.